MassBio Golf Classic Right Around the Corner!

golf 2014 web adFriday, September 5th is our 20th Annual MassBio Golf Classic to support MassBioEd at the beautiful Pine Hills Golf Club in Plymouth! The day will start at 8:00am with a continental breakfast and tee off is at 8:55am. There is still time to register for this fun and important fundraising event!

After golfers finish their day on the course, the fun continues with a reception, food, cocktails, and our live auction and raffles. Thanks to the generous donations from businesses and individuals all around New England, we are able to feature some great items for you to bid on and take home!

Taste of Cape Cod:

Alberto’s Ristorante, Yarmouth House, and The Beech Tree Cantina, Cape Cod

mb-golf-tourney2_0550

The Pinehills

Taste of Cambridge:

Catalyst, Commonwealth, Craigie on Main, Evoo, FUJI at Kendall, MexíCalí Burrito, The Friendly Toast, and Za

Hotel stays:

The Le Meridien, Hotel Marlowe, and the Omni Parker House

“Brew”haha:

Russell House Tavern, The Lansdowne Pub, Newburyport Brewing Company, and the Cambridge Brewing Company, Cambridge

Electronics:

Bose Sound Link Mobile Speaker III and the new Maker Bot Digitizer 3D printer donated by WB Mason

Travel & Elegant Retreats:

Pair of Jet Blue tickets from Colpitts, Day at the Mirbeau Inn & Spa – Pinehills, Plymouth, MA and the 5 star Euu Hotel & Resort in Palm Beach Florida

spa

Mirbeau Inn & Spa, Plymouth

Family Fun:

Boston Children’s Museum, Boston Duck Tours, Water Wizz and the F1 Racing Boston

Outdoor Adventures:

Wachusett Mountain Ski tickets and Charles River Canoe Stand Paddle Board rental

Arts & Culture:

Gift certificates for Art in Giving Fine Art and Bradford Renaissance Portraits of Palm Beach

Museum Mania:

MASS MoCA, MIT Museum, and Newport Mansions

Performance tickets:

Donated by the Berklee College of Music, Handel & Haydn Society and the SpeakEasy Stage Boston

Dining:

The Scarlet Oak Tavern, Hingham

Catering Services:

Salvatores and MexíCalí Burrito

Cool Science:

MassBioEd Learning Center course

 

 

Join us for a day of fun and help support STEM education in Massachusetts!

Spots are filling up so be sure to-

REGISTER NOW!

 

Thank you to our sponsors!


        Walmart

      emd    emd serono                emd millipore

Fisher Logo

 

randstad

 

     
veolia 2     Linde Logo

 

alexandria_logo   boston analytical          

 

eastern bank    forum 2    takeda millenium

 

         world courier

 

 

Sponsorship opportunities are available!

This well-attended industry event offers a great opportunity for maximum visibility! Click here to learn more or contact Larissa Fawkner at larissa.fawkner@massbio.org or 617-674-5100 for more information.

Welcome New Members

arryve newARRYVE helps our BioTech, Pharmaceutical, and Medical Device clients accelerate product development and manage R&D; develop operational strategy and implement supply chain improvements, and accomplish timely technology transfer and manufacturing scale-up. Link

 

commonwealth newCommonwealth Laboratories provides take-home hydrogen and methane breath tests to aid in the diagnosis of digestive distress. They have developed and implemented a mail-order laboratory model that allows physicians to simply stock and dispense Commonwealth Laboratories’ test kits to their patients from their office and Commonwealth Laboratories takes care of the rest. Link

 

Ge-healthcare-logoGE Healthcare Life Sciences provides expertise and tools for a wide range of applications, including basic research of cells and proteins, drug discovery research, as well as tools to support large-scale manufacturing of biopharmaceuticals. Link

 

 

Top 5 News Stories 8/16 – 8/22

Top 5 logo1) Report: Approved drugs by Bay State biotechs up 13 percent since 2010Boston Business Journal, August 22, 2014
The state’s biotech industry group, MassBio, put out its latest compilation of data to measure the local cluster on Wednesday. The Industry Snapshot, which has been an annual report since at least 2010, looks at all types of funding (venture capital, seed and NIH) as well as the amount of lab space. Notably, it takes an extra-close look at employment numbers in wake of the controversy following a Pioneer Institute report earlier this summer which found the job increase since the start of the 10-year Massachusetts Life Science Initiative to be much smaller than have other reports in recent years. Link

2) FDA approves Sanofi’s Gaucher disease drug Cerdelga – Reuters, August 19, 2014
The U.S. Food and Drug Administration said on Tuesday it has approved Sanofi SA’s drug Cerdelga to treat patients with type 1 Gaucher disease, a rare genetic disorder. The drug was developed by Sanofi’s Genzyme unit, which also developed the Gaucher disease drug Cerezyme. Cerdelga, known also as eliglustat, is a pill, while Cerezyme must be infused. Link

3) Biogen scores fresh MS advance with blockbuster Plegridy OK – Fierce Biotech, August 18, 2014
Billing it as the most important new innovation in the interferon drug class in a decade, Biogen Idec nailed down the FDA’s approval of Plegridy, a new multiple sclerosis drug that patients can easily inject themselves with once every two weeks. Essentially, Plegridy (peginterferon beta-1a) is a new-and-improved version of Avonex, Biogen’s once weekly interferon beta therapy for relapsing forms of MS. Link

4) GE unit to be based in Marlborough – Boston Globe, August 20, 2014
GE Healthcare, which last week said it would open a US headquarters in Massachusetts for its life sciences business, is set to disclose Wednesday that the business will be based in Marlborough, where the company expects to add about 220 jobs. The life sciences unit, called GE Healthcare Life Sciences, sells bioreactors, diagnostic tools, and other equipment used in biotechnology manufacturing globally. Link

5) Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer – Forbes, August 21, 2014
Illumina, the leading maker of DNA sequencing equipment, is partnering with Sanofi, AstraZeneca, and Johnson & Johnson to create a test for more mutations in dozens of genes that will be used first in clinical trials and, eventually, to help decide which patient should get which marketed drug. The tool is necessary because new cancer drugs like Roche’s Zelboraf and Astra’s Iressa work only against cells that became cancerous because of particular genetic mutations. Link

New Savings for MassBio Members on Nature & the Journal of Commercial Biotech

MassBIO_logo-largenature publishing groupJournal of Commercial Biotech

 

We know that access to scientific publications is critical for our members, so we are very excited to share that MassBio members can now save on leading scientific journals through new partnerships with Nature Publishing Group (NPG) and the Journal of Commercial Biotechnology, launched today!

Nature Publishing Group and the Journal of Commercial Biotechnology join the MassBio Purchasing Consortium to provide high-impact peer-reviewed research in all fields of science and medicine, in biotechnology business strategy and management information, and in current issues and industry trends. They will offer MassBio members significant savings on articles and subscriptions. We’re thrilled to be able to offer these important resources to MassBio members at a discount!

MassBio members are eligible for:

  • Special pricing on NPG’s Articles on Demand
  • Reduced site license pricing for the journals Nature and Nature Biotechnology
  • A free one-year digital institutional subscription of the Journal of Commercial Biotechnology
  • Discounts off personal or institutional subscriptions of the Journal of Commercial Biotechnology
  • And more!

See contract details here.

Click here for the full press release.

Welcome to the Purchasing Consortium, Nature Publishing Group and Journal of Commercial Biotechnology!

 

MassBio Industry Snapshot 2014 – Top 10 Highlights

stage icon industry stats 2014Today we released our annual MassBio Industry Snapshot for 2014! The 2014 MassBio Industry Snapshot shows Massachusetts leads in federal research funding and venture capital invested per capita, as well as research and development jobs, but that recent dips in seed-stage funding could negatively impact innovation long-term. Seed-stage funding in Massachusetts companies continues to grow, but 2014 investment must near $200 million to sustain five-year averages and ensure a solid startup environment into the next decade. You can read the full press release here and see the full snapshot here.

MA Seed-Stage Funding, Annual, 1999-2013

 

Here are the top 10 highlights:

1) Seed-Stage Deals & Investment – In the last five years, Massachusetts companies have received 33.4% of all seed funding for biotech. Over the past decade, Massachusetts has outperformed the nation in percentage of deals and investment at the seed-stage as a percentage of total venture funding.

2) Venture Investment - VC investment rose to $984M in 2013. Massachusetts received more than 21% of all VC investment in biotech in the U.S.

3) NIH-Funded Hospitals - The top five NIH-funded independent hospitals in the U.S. in 2013 are in Boston.

4) NIH-Funding Per Capita – Massachusetts continues to far exceed other leading NIH-recipient states.

5) Industry Employment - 57,642 – an all time high – accounts for over $7 billion in payroll.

Read the rest of this entry